B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression

EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells

(2020) Shaorong Yu et al.   ONCOGENE

Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7–H4 expression through the MEK/ERK signaling pathway

(2020) Zhiming Zhao et al.   CANCER LETTERS

B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma

(2020) Yan Chen et al.   PATHOLOGY RESEARCH AND PRACTICE

Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

(2019) Tina Gruosso et al.   JOURNAL OF CLINICAL INVESTIGATION

B7-H3-targeted radioimmunotherapy of human cancer

(2019) Benjamin B. Kasten et al.   CURRENT MEDICINAL CHEMISTRY

A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer

(2019) Akira Iizuka et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

(2019) Kyung Hae Jung et al.   CLINICAL CANCER RESEARCH

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

(2019) Hongwei Du et al.   CANCER CELL

Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma

(2019) Ken Hatogai et al.   BRITISH JOURNAL OF CANCER

The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial

(2019) Peter John et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8 + T Cells

(2018) Jing Li et al.   IMMUNITY

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

(2018) Kristina Buder-Bakhaya et al.   Frontiers in Immunology

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma

(2018) Chee Khoon Lee et al.   JAMA Oncology

Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma

(2018) Sarah Harris-Bookman et al.   INTERNATIONAL JOURNAL OF CANCER

Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations

(2018) Maria I. Toki et al.   Journal of Thoracic Oncology

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Drug response to PD-1/PD-L1 blockade: based on biomarkers

(2018) Qi Chen et al.   OncoTargets and Therapy

Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

(2017) Etienne Giroux Leprieur et al.   EUROPEAN JOURNAL OF CANCER

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

(2017) Murali Janakiram et al.   IMMUNOLOGICAL REVIEWS

Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis

(2017) Chee Khoon Lee et al.   Journal of Thoracic Oncology

New B7 Family Checkpoints in Human Cancers

(2017) Ling Ni et al.   MOLECULAR CANCER THERAPEUTICS

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

(2017) Lee Pai‐Scherf et al.   ONCOLOGIST

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients

(2017) Xiaofang Xing et al.   OncoImmunology

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer

(2017) Taisuke Yagi et al.   ANNALS OF SURGERY

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

(2016) Joohee Sul et al.   ONCOLOGIST

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Prevalence of rareEGFRgene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients

(2015) P. Krawczyk et al.   ANNALS OF ONCOLOGY

Molecular Portraits of Epithelial, Mesenchymal, and Hybrid States in Lung Adenocarcinoma and Their Relevance to Survival

(2015) M. J. Schliekelman et al.   CANCER RESEARCH

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES